As an SGLT2 inhibitor, ertugliflozin carries the same warnings as others in the class, including the potential for elevations in LDL cholesterol, as well as an increased risk of ketoacidosis, acute kidney injury and renal failure, urosepsis and pyelonephritis, genital mycotic infections, lower-limb amputation, and severe hypotension
Following the expiry of semaglutides patent in India (March 2021, 2026), the market changed dramatically.[13][14] 40+ Indian pharma companies launched generic GLP-1 medications[12] Prices dropped by ~80% Key players include: Sun Pharma Dr
The recent findings were reported in the Journal of Cosmetic Dermatology
Available in packs of 6, the sharp, beveled, curved, non-coring needle tip is perfect for septum piercing and is also recommended for manual GC injection, ensuring precise and efficient fluid transfer